Summary Eight children treated between 1977 and 1983 with the UK Children's Cancer Study Group's nonHodgkin lymphoma (NHL) and T-cell protocols have developed second malignancies within 7 years of commencing treatment. Five developed acute non-lymphoblastic leukaemia and a sixth died from infection while pancytopenic with a pre-leukaemic marrow. The other malignancies were cerebral astrocytoma and an undifferentiated low grade sarcoma.
Children with non-Hodgkin's lymphoma (NHL) have been shown to respond to intensive combination chemotherapy based on schedules such as the LSA2-L2 protocol (Wollner et al., 1976) . The UK Children's Cancer Study Group (UKCCSG) devised a similar protocol which was given to children presenting between July 1977 and July 1983 with NHL or T-cell leukaemia/lymphoma (Mott et al., 1984a, b) . Failure free survival rates at 4 years of 65% for children without mediastinal disease and 37% for T-cell leukaemia/lymphoma were achieved.
Recently three children treated with these protocols were reported to have developed acute myeloid leukaemia (Haworth et al., 1985 ; Rose et al., 1985;  Darbyshire & Mott, 1986 ). We report 3 additional patients with acute leukaemia or pre-leukaemia and 2 other cases of second malignancy viz: cerebral astrocytoma and undifferentiated sarcoma. A Kaplan-Meier estimate of the risk of second malignancy is derived for these 8 patients.
Patients, protocols and methods
The protocols are shown in Figure 1 . Remission was induced with two courses of cyclophosphamide, adriamycin, vincristine and prednisolone followed by cytosine and thioguanine. The remission was consolidated with intermediate dose intravenous methotrexate, with additional asparaginase, vincristine and prednisolone for the T-cell patients. Intrathecal methotrexate was given as prophylaxis for meningeal disease, together with cranial radiotherapy for T-cell disease and patients were allocated at random either to no further treatment or to low dose radiation (15Gy) to the initial sites of bulk disease. This was followed by maintenance chemotherapy including the alkylating agents cyclophosphamide and CCNU. Total treatment time from first diagnosis was 2 years.
There were 261 patients registered in the UKCCSG studies, 166 treated with NHL, 95 with the T-cell protocol. The eight second malignancies reported here were among these 261 patients. Their case records and histological specimens have been reviewed. The staging system is that of Murphy and Hustu (1980) . The three patients reported previously were case 4 (Haworth et al., 1985) , case 5 (Darbyshire & Mott, 1986) and case 6 (Rose et al., 1985) . 
Results
The child with Hodgkin's disease but treated with the NHL protocol subsequently developed a myxoid sarcoma. This was of different histological characteristics from the malignant fibrous histiocytoma reported in another series (Suster, 1986) . Case 3, with early meningeal disease developed a secondary cerebral astrocytoma and died without further treatment.
Six of the eight patients developed acute myeloid leukaemia or pre-leukaemia, the characteristics of which are given in Table II . The last case developed acute myeloblastic leukaemia but the other five cases all had monocytic or myelomonocytic features. The child described in case 7 had severe neutropenia for several months and marrows taken during this time showed evolution towards M4 myeloid leukaemia. The leukaemic cells in two patients had chromosome abnormalities, including an 11:16 translocation in one.
Further chemotherapy was given to 6 of the 8 children. The girl who developed the undifferentiated sarcoma responded to a combination of ifosfamide, etoposide and cisplatinum. Two of the children with acute myelomonocytic leukaemia remain in complete remission. Case 1 was treated on the basis of the BFM protocol (Creutzig et al., 1985) for acute myeloid leukaemia and case 5 has had a successful bone marrow transplant after partial response to cytosine arabinoside and etoposide. He was conditioned with cyclophosphamide and irradiation before grafting from his HLA identical brother. These 8 patients who developed second malignancy include 7 boys and 1 girl, whereas the trial had a ratio of 3:1 boys. If the girl is excluded as she did not have NHL or T-cell leukaemia then it might be surmised that boys are at special risk of developing secondary disease, especially myeloid leukaemia. The mean age of the children in this report (9 years) does not differ significantly from that in the trial (8 years).
The incidence of second malignancy based on KaplanMeier statistical analysis (Kaplan & Meier, 1958) , is shown in Figure 2 and shows a risk of 7.8% at seven years. A similar analysis excluding case 8, the boy with Bloom's syndrome (see Discussion) gives an incidence of 6.7% at seven years.
Discussion
This paper describes a relatively high incidence of secondary myeloid leukaemia in a group of children with NHL. A previous study (Mike et al., 1982) included 1,050 children treated for NHL and followed for up to 20 years and did not describe any patients with secondary myeloid leukaemia. A later review by the same late effects study group describes one child with leukaemia among 12 second malignancies in patients surviving NHL. However, all the children in this paediatric series were diagnosed before 1970, and had not therefore received the kind of chemotherapy which has so greatly improved prognosis subsequently (Wollner et al., 1976) . There were no cases of myeloid leukaemia in a series of 31 second malignancies among 630 adults treated for NHL (MacDougall et al., 1981) .
A recent editorial (Lancet, 1985) however, has commented on the incidence of secondary leukaemia in lymphoma patients. Evidence of myeloid leukaemia arising in adult patients treated for both Hodgkin's disease and NHL is described by Pedersen-Bjergaard et al. (1985) with the report of 16 NHL patients developing myeloid leukaemia and by Michels et al. (1985) who reported 4 such patients. These papers also comment on the incidence of leukaemia after Hodgkin's disease. The earlier review by Grunwald & Rosner (1982) had already collated an extensive series of 216 cases of Hodgkin's disease who developed acute myeloid leukaemia. This paper is especially relevant to our study as it shows a high proportion of myeloblastic leukaemia (45%) similar to the high incidence of M2 leukaemia shown by Michels (1985) in contrast to our results. Also, the paper attempts to show that the majority of their patients had received both alkylating agents and radiotherapy as had our patients.
The association of radiotherapy with second malignancy is well known. One report (Potish et al., 1985) (Sawitsky et al., 1966) , but even if this child is excluded our estimate gives an incidence of 6.7% second malignancies at 7 years. A comparable figure of 9.9% at 9 years was reported in adult Hodgkin's disease (Pedersen-Bjergaard & Larsen, 1982) .
The secondary leukaemias described in our series had chromosome abnormalities documented in two of the three cases studied. Similar findings were reported in the studies of Michels (1985) and Pedersen-Bjergaard et al. (1984) .
Further trials of treatment for NHL in children should examine the potential role of intensive chemotherapy and radiotherapy as causative agents of secondary malignancy, especially myelomonocytic leukaemia in boys. Adjuvant radiation was discontinued by our Group on the basis of the results of these randomised trials (Mott et al., 1984a, b) . It will be informative to follow the group who received no adjuvant radiation, both in the trial cohort and in the subsequent patients who received a modified chemotherapy regimen.
